Jubilant Therapeutics Inc, a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of the investigational new drug application (IND) for JBI-802, a novel, oral, potent and selective dual inhibitor of LSD1 and HDAC6, for the treatment of small cell lung cancer (SCLC), treatment-induced neuro-endocrine prostate cancer (NEPC) and other mutation-defined neuroendocrine tumors.

The Phase 1/2a trial is an open-label, two-part dose escalation and expansion study designed to define the safety profile and preliminary activity of JBI-802 in participants with advanced solid tumors. The study population will include patients with locally advanced or metastatic solid tumors whose disease has failed prior standard therapy.  Expansion cohorts of participants with SCLC, NEPC, and other neuroendocrine-derived cancers will be enrolled to obtain additional safety and efficacy data.

Mr. Hari S Bhartia, Chairman, Jubilant Therapeutics said “We are proud to see our fully in-house discovered program lead our transformation to a clinical stage biotech. This validates the powerful biotech platform that we have built. Jubilant’s objective is to leverage our decades of internal drug discovery and development expertise to create important new medicines by advancing novel molecules against validated targets or first-in-class molecules against newly discovered targets”

“JBI-802 is our most advanced drug candidate and our first to enter into clinical development from a broad pipeline of truly innovative molecules. Our chosen tumor types have high unmet medical needs that can translate to faster approval paths” said Syed Kazmi, Chief Executive Officer of Jubilant Therapeutics.

About JBI-802

JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6. It targets stem cell modulation by inhibiting LSD1 and modulates immune suppression with isoform selective HDAC6 inhibition. Preclinical research has demonstrated its synergistic anti-tumor activity, which is superior compared to inhibiting either target alone, and has a favorable safety profile with no significant safety concerns or accumulation. It will be evaluated in both solid tumors, such as small cell lung cancer and neuroendocrine prostate cancer, and hematological cancers such as acute myelogenous leukemia, myelodysplastic syndrome, and other myeloproliferative cancers.

About Jubilant Therapeutics

Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically defined patient populations. The company is progressing its most advanced program - first in class dual inhibitor of LSD1/HDAC6 to Phase 1/2a, followed by additional INDs with novel brain-penetrant modulators of PRMT5 and PDL1, as well as PAD4 inhibitors in oncology and inflammatory indications. Jubilant Therapeutics is headquartered in Bedminster, NJ, and guided by globally renowned scientific advisory board and key opinion leaders. For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.

PR Contact

Robert Flamm / Katie Larch / Dr. Grace Kim
rflamm@burnsmc.com / klarch@burnsmc.com / gkim@burnsmc.com

IR Contact

Eric Goldstein / Brian Hicks
egoldstein@lifesciadvisors.com / bhicks@lifesciadvisors.com

Spokane, WA - November 11, 2021: Jubilant HollisterStier LLC, a pharmaceutical contract manufacturer that is part of Jubilant Pharma Limited, announced plans to host a groundbreaking ceremony on Wednesday, November 17, 2021 at 11:00 am PT at their Spokane, Washington facility. The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%.

“Based on our trajectory analysis of the sterile injectable market, as well as ongoing conversations with existing partners, there is need to add capacity at our existing facility,” said Amit Arora, President, Jubilant HollisterStier. “The pandemic has fortified our commitment to being ready to quickly support the innovative pharmaceutical partners we work with, whose drugs play an instrumental role in saving the lives of many.”

“Continuous improvements and growth are at the core of our values at Jubilant. That is why we are very pleased to make this investment of US$92Mn approx. in a state-of-the-art filling machine that features the highest degree of quality and compliance to meet current regulatory standards and service our customer’s need even better” stated Pramod Yadav, CEO Jubilant Pharma Limited.

The new filling line will be commercially available by the end of 2024. Jubilant HollisterStier has already begun filling the 250 new roles created to support this expansion and is actively recruiting at this time.

About Jubilant HollisterStier LLC

Jubilant HollisterStier LLC, a part of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full-range of support to streamline the manufacturing process, from process qualifications through commercial release.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radiopharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

November 11, 2021 – San Diego, CA, USA & Bengaluru, India — Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.  Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small molecule oncology research programs. Turning Point is a precision oncology company developing next-generation therapies that target genetic drivers of cancer.

Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited’s newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India. It’s Chemistry Innovation Research Center has an initial capacity of 500 FTEs enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.

Commenting on this expansion, Giuliano Perfetti, Chief Executive Officer, Jubilant Biosys Limited said, “We are delighted to unveil our newly built Chemistry Innovation Research Center, Greater Noida for Turning Point’s and our other clients’ project needs and we are looking forward to accelerating their programs through this site.”

“We are excited to continue our relationship with Jubilant Biosys Limited as they start using their CIRC. They continue to provide skilled contract services for challenging synthetic chemistry projects while realizing the importance of short cycle times to deliver and provide critical in-vitro ADME data for our growing portfolio.” said Siegfried Reich, Ph.D., chief scientific officer, Turning Point Therapeutics.

About Jubilant Biosys Limited

Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development services for global pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in functional services in chemistry including- computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery expertise with a track record of working on over 80 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases. For more information, please visit: www.jubilantbiosys.com 

Business Development Contact:
Ravichandran S
bd@jubilantbiosys.com

About Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Media Contact:
Scott Lipman
ir@tptherapeutics.com
858-876-3985

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

BEDMINSTER, New Jersey – Nov 10, 2021 – Jubilant Therapeutics Inc., a private biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that its senior management team led by Syed Kazmi, Chief Executive Officer will participate in one-one-one meetings and present at the following investor conferences:

• Jefferies London Healthcare Conference

Date: Thursday, November 18th and Friday, November, 19th, 2021 (virtual)

• Piper Sandler Annual Healthcare Conference 2021

Date: Monday, November 29th, 2021 (virtual)

The Board of Jubilant Pharmova Limited met today to approve financial results for the quarter ended September 30, 2021.

Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said:

“The Company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while Radiopharma, Allergy and CMO businesses reported growth on a YoY basis, the API business’ performance was lower on a higher base last year and Generics business witnessed headwinds due to temporary pricing pressure in the US market. The Generics business was also affected during the quarter by the Import Alert at the Roorkee plant and by impact of the Industry wide impurity issue in certain sartan products that led to lower sales and some product withdrawal.
In our Contract Research and Development Services business, we witnessed strong growth both YoY and sequentially driven by continued strong demand from our customers for our Drug Discovery Services.
In the Proprietary Novel Drugs business, our plans are on track to take one program to the clinical stage by end of this financial year.
During H1’FY22, we grew our revenues by 20% YoY and improved our EBITDA margins by 2.44% vs. H1’FY21 due to recovery in Radiopharma business and strong performance in Allergy Immunotherapy, CMO, API and Contract Research businesses.
I would like to mention that over the medium term, we have very strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.”

Q2’FY22 Highlights

A. Consolidated financials

• Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21
• Reported EBITDA at Rs 344 Crore versus Rs 353 Crore in Q2'FY21
• Finance costs at Rs 35 Crore vs. Rs 46 Crore in Q2'FY21
• PAT was at Rs 143 Crore as compared with Rs 147 Crore in Q2'FY21
• EPS is Rs 8.97 versus Rs 9.21 in Q2'FY21
• Capital expenditure for the quarter was Rs 131 Crore

Segment Wise Analysis

B. Pharmaceuticals Segment

• Radiopharma business witnessed improvement in sales YoY, however pace of recovery during the quarter was affected by increase in COVID-19 cases in the US
  • We continue to maintain majority market share
  • Ruby-Fill installations during the quarter was affected by the higher COVID-19 cases in the US. Doubling of RUBY-FILL manufacturing capacity complete, which will enable continued growth in Rb-82 market.
  • NDA for I131 MIBG clinical trials both for phase II and phase III is progressing satisfactorily.
  • Radiopharmacy business witnessed steady performance YoY, however volumes impacted during the quarter due to COVID-19. Turnaround plan is on track with positive outcome over the last two quarters
• Allergy Immunotherapy reported robust performance both YoY and sequentially with strong recovery from COVID-19 backed by healthy growth in revenues resulting from volumes higher than pre COVID levels
• CMO business revenue grew YoY based on continued strong demand from customers as well as due to COVID related deals
• Performance of API business was lower year-on-year due to higher base last year but sequentially witnessed strong growth with stable margins
• Generics business performance adversely affected due to the following
  • Pricing pressure in the US market
  • Lower volumes due to import alert at Roorkee plant
  • Industry wide impurity issue in certain sartan products that affected performance as a result of voluntary withdrawals
  • This was partly offset by higher remdesivir sales
• With regards to Roorkee import alert, our remediation activities are ongoing as per plan and we expect to complete the same early next CY.

C. Contract Research and Development Services Segment

• Revenue at Rs 108 Crore increased by 44% YoY led by robust volume growth
  • Higher demand from biotech companies for integrated services, functional chemistry and DMPK, Discovery Biology and Clinical trial data management support trough Trial stat, Canada.
  • Continue to witness strong demand conditions in this business
• Reported EBITDA at Rs 35 Crore vs. Rs 21 Crore in Q2'FY21 with a margin of 32.9% vs. 27.4% in Q2'FY21

D. Consolidated financials

• Revenue was Rs 3,292 Crore versus Rs 2,747 Crore in H1'FY21
• Reported EBITDA at Rs 723 Crore versus Rs 536 Crore in H1'FY21
• Finance costs at Rs 69 Crore vs. Rs 94 Crore in H1'FY21
• Average blended interest rate for H1'FY22 stood at 4.62%
• PAT was at Rs 303 Crore as compared with Rs 182 Crore in H1'FY21
• EPS is Rs 19.06 versus Rs 11.44 in H1'FY21
• Capital expenditure for the period was Rs 238 Crore

Segment Wise Analysis

E. Pharmaceuticals Segment

• Pharmaceuticals revenue at Rs 3,085 Crore vs. Rs 2,612 Crore in H1’FY21
• Pharmaceuticals EBITDA at Rs 686 Crore vs. Rs 521 Crore in H1’FY21. EBITDA margin of 22.2% as compared to 20% in H1’FY21
• Radiopharma business saw recovery in H1’FY21. With COVID-19 cases coming down, we expect this trend to continue
• Radiopharmacy business came close to pre-COVID levels with pick up in nuclear medicine procedures in Q1’FY22 but was again impacted by COVID-19 in Q2’FY22. Turnaround plan is on track
• Allergy Immunotherapy reported robust performance with strong recovery from COVID-19 backed by healthy growth in revenues resulting from volumes higher than pre COVID levels
• Growth in CMO business led by strong demand witnessed from customers as we leveraged our capabilities to meet significant COVID-19 related demands
• API revenue higher with lower base as in Q1FY21 there was a production impact due to COVID-19
• Revenue growth was driven by higher sales of Remdesivir during the period. Impact of Import Alert and voluntary withdrawal of some sartan products in Q2’FY22 limited the revenue growth

F. Contract Research and Development Services Segment

• Revenue at Rs 196 Crore increased by 49% YoY led by robust volume growth
  • Higher demand from biotech companies for integrated services, functional chemistry and DMPK, Discovery Biology and Clinical trial data management support trough Trial stat, Canada.
  • Continue to witness strong demand conditions in this business
• Reported EBITDA at Rs 70 Crore vs. Rs 38 Crore in Q2'FY21 with a margin of 35.6% vs. 29.2% in H1'FY21

Business Outlook

Pharma: In radiopharma, we continue to build a long term pipeline of radiopharmaceuticals and are executing a turnaround plan of radiopharmacies. Medium-long term outlook remains robust. Allergy business well placed to grow strongly with healthy margins over the medium term. We expect the CDMO segment to witness near term correction as COVID related product demand will shift as the pandemic subsides. We expect performance of Generics in current year to be impacted due to the import alert, pricing pressure in the US market and new industry wide impurity issue in sartans

Contract Research and Development Services (CRDS): The business will continue to grow especially with commissioning of the State of the art Greater Noida facility. We continue to evaluate further capex plans in this business given the strong demand climate

Investments and Growth: We are accelerating capacity expansions to create new capabilities by almost tripling the investment over previous year. We expect to incur capex of Rs 700-800 Crore in FY22 that includes expansion at Spokane site by 50% by end of CY 24 and enhancement of CRDS capabilities and capacities. In view of the strong demand from our customers, we have approved further expansion of the Greater Noida facility which will deliver both Chemistry and DMPK services

Proprietary Novel Drugs: We plan to take one drug candidate to Phase I clinical trials in H2’FY22. IND filings for additional programs expected in 2022. Efforts underway towards creating shareholder value through an external capital raise/ potential partnering with major global pharmaceutical companies.

Consolidated effective tax rate: ETR of Jubilant Pharmova Limited for H1’FY22 is 33.3%. The company’s cash tax outflow is estimated to be at approximately 24% for the next three years based on the current tax structure in key geographies. After exhaustion of the MAT credit, the Company’s effective tax rate is expected to come down to around 25% in three years’ timeframe

Income Statement – Q2 & H1'FY221,2

1. All figures are in Rs Crore unless otherwise stated
2. Q2’FY21 and H1’FY21 financials include only the continuing business

Earnings Call details

The company will host earnings call at 5.00 PM IST on October 22, 2021

Participants can dial-in on the numbers below
Primary Number: + 91 22 6280 1141 / + 91 22 7115 8042
Toll Free Numbers:
USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448

Replay: October 22 to October 29, 2021
Dial-in: +91 22 7194 5757/ +91 22 6663 5757
Playback ID: 55416#

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

For more information, please contact:

For Investors

Vineet V Mayer
Ph: +91 120 436 1103
E-mail: vineet.mayer@jubl.com

Siddharth Rangnekar |Karl Kolah
CDR India
Ph: +91 97699 19966 / 9833010478
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

For Media

Sudhakar Safaya
Ph: +91-120 436 1062
E-mail: sudhakar.safaya@jubl.com

Clayton Dsouza
Madison Public Relations
E-mail: clayton.dsouza@madisonpr.in
Phone number: +91 9930011602

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Noida, October 7, 2021: The Schwab Foundation for Social Entrepreneurship, the sister organisation of the World Economic Forum, and the Jubilant Bhartia Foundation of Jubilant Bhartia Group today conferred Pranshu Singhal of KARO SAMBHAV with the prestigious Social Entrepreneur of the Year Award - India 2021. The award was presented by Prof. K. VijayRaghavan, Principal Scientific Adviser to the Government of India at a virtual ceremony in presence of eminent personalities from different fields from across the world.

Felicitating the winner and congratulating the finalists of this year’s SEOY Award India 2021, Prof. K. VijayRaghavan, Principal Scientific Adviser to the Government of India said, “This global pandemic has been a major crisis and the social entrepreneurs have come forward in each section of the society as emergency rescuers for the most vulnerable, by stretching their means to the maximum possible. We need to take important lessons from these change makers working at the grass-roots offering unique solutions to seemingly impossible challenges. Recognising their ideas, work and contributions towards solving challenges will help them scale their work and increase their efficiency. I compliment the Schwab Foundation and the Jubilant Bhartia Foundation for this unique initiative of recognising these social entrepreneurs for over a decade now.”

The SEOY India Award 2021 winner Pranshu Singhal from Karo Sambhav is working to make circular economy possible and is enabling enterprises to close their material loops. Karo Sambhav covers e-waste, plastic packaging waste, battery waste and glass and continues its exploration towards less scrutinised sectors like mattresses and textiles. Pranshu aims to shape and catalyse the set-up of a well-governed and accountable end-of-life waste management industry with transparent practices.

Ms. Hilde Schwab, Co-Founder and Chairperson, Schwab Foundation for Social Entrepreneurship and Professor Klaus Schwab, Founder & Executive Chairman of, World Economic Forum and Co-Founder of the Schwab Foundation for Social Entrepreneurship commended the role of social entrepreneurs and congratulated the winner & finalists. They shared, “The global pandemic has emphasised the critical role of social innovators in identifying urgent needs and responding to realities on the ground. This year’s winner and finalists of the Social Entrepreneur of the Year India Award represent the ethos of social innovation and entrepreneurship. They are actors who have selflessly dedicated their lives to improving the state of the world by reaching and strengthening marginalised communities on the fringes of society. Social innovators are pioneering agents of change, revitalising the way our institutions operate, and are critical to achieving a more equitable world. The Schwab Foundation for Social Entrepreneurship is proud to have been partnering with Jubilant Bhartia Foundation over the past 12 years to award social innovators from India who are not only driving change but are also shifting systems towards a more inclusive and sustainable future.”

Applauding the winner and the finalists, Mr. Shyam S Bhartia, Chairman and Founder and Mr. Hari S Bhartia, Chairman & Co-Founder, Jubilant Bhartia Group and Founder Directors of Jubilant Bhartia Foundation said, "The pandemic brought to the forefront the extraordinary role of social entrepreneurs as front line workers and showcased their vast reach and penetration in the country. The social entrepreneurs have acted as Corporate India’s implementation partners, working hand-in-hand. Despite the shattering second wave of COVID-19, this year we received close to 100 diverse submissions out of which 28 were women social entrepreneurs & two of them have been selected as finalists. The award submissions reflect the indomitable spirit and resilience of the social entrepreneurs. The social entrepreneurs have also set an example for collaborative efforts worldwide by displaying the power of working together and leveraging each other’s strengths. To amplify the work of these social entrepreneurs especially on post COVID rehabilitation, we now part of the World Economic Forum’s initiative - the ‘COVID Response Alliance for Social Entrepreneur’s. The alliance will provide a platform to showcase the work done by the social entrepreneurs in India as well as globally. Kudos to all our finalists and the winner who have made through several stringent rounds of evaluation. This year marks the 12th year of our strong partnership with the Schwab Foundation for Social Entrepreneurship. Over the years we have seen over 1700 high impact submissions. We stay committed to recognising and empowering these high spirited individuals in their endeavours.”

Pranshu Singhal on winning the SEOY Award India 2021 shared, “We are today in the decade of action. We need a movement where people, organisations, enterprises, governments collaborate and co-create solutions. I thank the SEOY India Award for kick starting the journey of making things circular. This award will go a long way in helping us be a catalyst in this space.”

Pranshu Singhal from Karo Sambhav will join the Schwab Foundation for Social Entrepreneurship’s Community, the world’s largest and prestigious network of social innovators from around the world. The winner of SEOY Award also participates in World Economic Forum (WEF) events which offer unique opportunities to engage with global decision-makers from the public, corporate, media, academic and civil society sectors. The other finalists of SEOY Award India 2021 were Dr. Aparna Hegde from ARMMAN, Seema Prem from FIA GLOBAL and Dr. Shuchin Bajaj from UJALA CYGNUS.

The SEOY Award aims to recognise promising and successful social entrepreneurs, who are key enablers of inclusive growth addressing challenges in numerous areas with excellence in large-scale, system change models. The SEOY Award - India has established itself as one of the most reputable awards for social entrepreneurs in India. This year the award celebrates its 12th year. In 2010, the Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation came together to promote social innovation in India through the Social Entrepreneur of the Year (SEOY) Award – India and has since recognised and supported the growing field of social innovation in India.

This year’s jury members for the award included, Ms. Shobhana Bhartia, Chairperson & Editorial Director, HT Media Ltd; Ms. Hilde Schwab, Chairperson & Co – Founder, Schwab Foundation for Social Entrepreneurship; Mr. T V Narendran, CEO & Managing Director, Tata Steel Ltd & President, CII; Ms. Sudha Pillai, Former Member Secretary, Planning Commission, Government of India; Mr. P R Ganapathy, Regional Director, Stanford Seed, India; Ms. Rohini Nilekani, Chairperson, Arghyam Foundation; Ms. Ashraf Patel, Founder, Pravah & Commutiny Youth Collective Winner SEOY 2020 and Mr. Ramraj Pai, Chief Executive Offi­cer, India Impact Investor’s Council (IIC).

About the winner:

Pranshu Singhal from Karo Sambhav aims at making recycling a way of life in India and beyond.  The organisation is working to make circular economy possible by building systems, platform, and infrastructure for end-of-life (eol) waste collection and recycling, and utilisation of recovered materials. It is creating an inclusive social movement, which drives long-term behaviour change, ensures participation from different sections of the society, is supported by the producers and provides a fair value and opportunity to all the stakeholders involved in the waste management value chain. It collaborates with producers on circular economy and EPR frameworks for multiple waste categories.

Through pioneering practices, and strategic alliances with organisations like IFC, GIZ, ILO, WEEE Forum, PACE, Karo Sambhav’s programmes are helping shape contours of the eol waste management industry. Together with the world’s leading CPG brands, Karo Sambhav launched India’s first industry-led venture to solve the plastic waste crisis. It is the first organisation in the country to design and implement solutions for nationally regulated as well as voluntary waste streams. It covers e-waste, plastic packaging waste, battery waste and glass and continues its exploration towards less scrutinised sectors like mattresses, textiles.

A critical aspect of Karo Sambhav is its engagement with the informal sector (waste pickers, and aggregators). It has helped increase the average incomes of the marginalised informal waste pickers by providing them a fair value, built capacities and created livelihoods. Karo Sambhav’s technology platform (mobile and web-app) gives it an edge by establishing transparency and traceability across the waste value chain and allows multiple stakeholders to be on a single platform. Karo Sambhav has collected and enabled responsible recycling of over 23,000 MT of e-waste and plastics waste in the past four years and has prevented 21,100 MT of CO2 emissions. It has engaged with over 3,000 schools, over 500 bulk consumers, more than 5,000 informal workers in over 60 cities across 29 States of India.

Note to the Editors:

Schwab Foundation for Social Entrepreneurship was co-founded by Hilde Schwab and Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. For over twenty years, the Schwab Foundation for Social Entrepreneurship has supported the world’s leading social innovators in their efforts to create a more just, equitable, and sustainable world. The Schwab Foundation provides unparalleled platforms at the regional and global level to highlight and advance leading models of sustainable social innovation.

Learn more at www.schwabfound.org and follow on:
Twitter: https://twitter.com/schwabfound
Facebook: https://www.facebook.com/schwabfound/
LinkedIn: https://www.linkedin.com/company/schwab-foundation-for-social-entrepreneurship

Jubilant Bhartia Foundation (JBF), established in 2007, is the not-for-profit organisation of the Jubilant Bhartia Group. It focuses on conceptualising and implementing the Corporate Social Responsibility initiatives (CSR) for the Group. The Jubilant Bhartia Foundation’s activities include various community development work, healthcare programs, cultural and sports events, environmental preservation initiatives, vocational training, women empowerment, educational activities and promotion of Social Entrepreneurship.

Learn more at www.jubilantbhartiafoundation.com and follow on:
Twitter: https://twitter.com/indiaseoy
Facebook: https://www.facebook.com/IndiaSEOY
LinkedIn: https://in.linkedin.com/company/jubilantbhartiafoundation

For media queries, please contact:
Vivek Prakash
Jubilant Bhartia Foundation;
Ph: +91 120 436 1804/ 1811;
E-mail: vivek.prakash@jubl.com

BEDMINSTER, New Jersey – September 30, 2021 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan,  clinical study design and dosing strategy for the Phase I/II trial of JB1-802, a dual inhibitor of LSD1 and HDAC6, for the treatment of small cell lung cancer, treatment-induced neuro-endocrine prostate cancer and other mutation-defined neuroendocrine tumors.

A pre-IND meeting provides the drug development sponsor an opportunity for an open communication with the FDA to discuss the IND development plan and to obtain the agency’s guidance regarding planned clinical evaluation of the sponsor’s new drug candidate. After reviewing the preclinical data provided, plans for additional data generation and the Phase I/II clinical trial protocol, the FDA addressed Jubilant Therapeutics’ questions, provided guidance and aligned with the sponsor on the proposed development plan for JBI-802.

"We appreciate the FDA's guidance as we endeavor to find an innovative new treatment for high unmet-need tumors with devastatingly low survival rates” said Hari S Bhartia, Chairman, Jubilant Therapeutics Inc.

"We are pleased with the outcome of the pre-IND meeting with the FDA and plan to submit the IND application by the end of 2021" said Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc.

About Jubilant Therapeutics

Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically defined patient populations. The Company plans to file an IND later this year for the first in class dual inhibitor of LSD1/HDAC6, followed by two additional INDs in 2022 with novel modulators of PRMT5 and PAD4 in oncology and inflammatory indications. Jubilant Therapeutics is headquartered in Bedminster NJ and guided by globally renowned key opinion leaders and scientific advisory board members.  For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.

Media Contact

Susan Sharpe, +1 781-235-3060
MacDougall
ssharpe@macbiocom.com

The following accomplished high-impact social entrepreneurs have been selected as finalists for the SEOY Award – India 2021:

1. Aparna Hegde, ARMMAN; www.armman.org

2. Seema Prem, FIA GLOBAL; www.fiaglobal.com

3. Pranshu Singhal, KARO SAMBHAV; www.karosambhav.com

4. Shuchin Bajaj, UJALA CYGNUS; www.ujalacygnus.com

An eminent jury panel comprising industry stalwarts and distinguished personalities from different fields and backgrounds will select the final winner of the award.

The winner of the ‘Social Entrepreneur of the Year’ Award - India 2021 will be announced in a virtual ceremony on Thursday, October 7th, 2021. The virtual award ceremony will be attended by various dignitaries from across the globe to celebrate and appreciate the exemplary contribution of these high spirited individuals.

The SEOY Award aims to recognise promising and successful social entrepreneurs, who are key-enablers of inclusive growth addressing challenges in numerous areas with excellence in large-scale, system change models. The winner of the SEOY Award - India will join the world’s largest network of high-impact social enterprises affiliated with The Schwab Foundation for Social Entrepreneurship.

The finalists of the SEOY Award – India 2021 are high-spirited transformational individuals selected through the stringent criterion of evaluation, based on several parameters, including COVID-19 response & efforts, background research, personal & on-ground team interactions, impact assessment, expert reviews and reference checks.

The chosen finalists are tech-enabled experts working in fields of maternal and child health care, financial services inclusion of the underserved, circular economy (recycling of e-waste, plastic packaging waste), battery waste and glass and high-quality tertiary healthcare services to the under-privileged. Using ground-breaking innovation in their respective initiatives, these social entrepreneurs are bringing impact through the inventive use of technology, working on frameworks of Extended Producer Responsibility (EPR), development of AI powered Fintech platform, availability of low-cost super-specialty hospitals in tier-2 & tier- 3 cities of India.

The SEOY Award – India 2021 opened for applications in March 2021 and received over 100 diverse submissions from 28 cities of India including 28 from women social entrepreneurs. The categories of the intervention included healthcare, clean technology, media communication, disability, energy, enterprise development, labour conditions, microfinance, nutrition, sustainable farming and water & sanitation.

The SEOY Award - India has established itself as one of the most reputable awards for social entrepreneurs in India. This year the award celebrates its 12th year. In 2010, the Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation came together to promote social innovation in India through the Social Entrepreneur of the Year (SEOY) Award – India and has since recognised and supported the growing field of social innovation in India.

Brief Descriptions of the Finalists:

Dr Aparna Hegde from ARMMAN
Founder and Managing Trustee
Sector: Healthcare
Established: 2008
www.armman.org

ARMMAN is a non-profit organisation that leverages technology to create cost-effective, scalable, non-linear, systemic solutions with proven impact to improve maternal and child health in the first five years. ARMMAN’s programs provide pregnant women/mothers with critical preventive information to improve health seeking behaviour. It also supports health workers and systems with technology-enabled comprehensive training.

It adopts a ‘tech plus touch’ approach and leverages the health worker network of the Government and its partner NGOs along with the deep mobile penetration. It is currently implementing its ‘Kilkari’ (largest mobile-based maternal messaging program across the world) & ‘Mobile Academy’ program (largest health-worker training program globally), in partnership with the Ministry of Health and Family Welfare, Government of India. ARMMAN has also partnered with Google AI for Social Good for predictive analytics/AI and with Turn.IO to pilot WhatsApp as a health platform to improve maternal and child health.

It has reached over 25 million women and children and 197,000 frontline health workers in 19 states of India with aims to reach 123 million women and children and 1 million health workers by 2030.

Seema Prem from FIA GLOBAL
CEO, Co-Founder
Sector: Financial Services & Social Inclusion
Established: 2012
www.fiaglobal.com

FIA is an impact ‘fintech’ organisation that redefines the way financial services are distributed to low income individuals in South Asia, particularly women. FIA’s AI powered Fintech platform - FINVESTA aggregates, designs and delivers sachet financial products to rural customers through its wide network of banking agents. With its distribution expertise it makes financial services more accessible, intuitive and indispensable to the underserved communities. Started to tap the ‘un-banked’ market in India.

FIA today offers an umbrella of services at its inclusion centres which comprises of accounts, cash in/cash out, fund transfers global remittances, investment and protection products, credit and distribution of Government subsidies among others. These services are specially designed for women and women-owned businesses and other financially-excluded populations who live or work in un(der) served geographies. FIA’s local banking agents receive start-up and ongoing training and professional development services from FIA.

FIA has one of the largest rural digital banking infrastructures serving 40 million customers through 30,000 inclusion centers. It aims to provide banking services to over 100 crore people across India, Nepal and Bangladesh.

Pranshu Singhal from KARO SAMBHAV
Founder
Sector: Waste Management 
Established: 2016
www.karosambhav.com

Karo Sambhav is a social enterprise, with an aim to make recycling a way of life for people.  It covers e-waste, plastic packaging waste, battery waste and glass and continues its exploration towards less scrutinised sectors like mattresses, textiles and tyres. Karo Sambhav collaborates with leading enterprises, strategic alliances and governments on ‘Circular Economy’ and ‘Extended Producer Responsibility’ (EPR) frameworks. Karo Sambhav utilises its core strengths of deep technical expertise, grassroots action, technology and systems thinking approach to create impact at scale.

A critical aspect has been the successful integration of the informal sector with the EPR programmes as collection partners. This has resulted in the growth of over 200 formal businesses and a channelisation of USD 8.2 million in collective revenue, while creating new pathways of formal job growth.  Karo Sambhav has collected and enabled recycling of over 23,000 MT of e-waste and plastics waste in the past four years and has prevented 21,100 MT of CO2 emissions. It has directly engaged 3 million people in 60 cities in 29 states of India through its on-ground awareness programmes with over 3,000 schools and 500 organisations.

Dr. Shuchin Bajaj fromUjala Cygnus Healthcare Services
Founder Director
Sector: Healthcare
Established: 2011
www.ujalacygnus.com

Ujala Cygnus Group of Hospitals was established with an aim to address the tertiary healthcare needs of the poorest of the poor individuals. It aims to provide global standards of healthcare to the masses at affordable prices. It aims to do so by bringing the revolution of super-specialty tertiary health care facilities to tier-2 & tier- 3 cities of India. In addition, it also ensures free medicines and offers discounts on pharmacy, consultancies and surgeries to the economically weaker sections of the society. Ujala Cygnus also mobilises the community on various facets of health awareness hence contributing to healthcare equity. It conducts CMEs (Continuous Medical Education) programmes (over 4000 conducted) through its expert doctors to other medical practitioners (over 50,000 reached) in the community to create sustainable healthcare solutions.

It is currently present in 14 districts and four states of India. Each day Ujala hospitals perform over 70 surgeries, provide consultation to over 650 patients and admit over 200 patients on an average. It plans to expand its presence to five new states in near future.

Note to the Editors:

Schwab Foundation for Social Entrepreneurship was co-founded by Hilde Schwab and Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. For over twenty years, the Schwab Foundation for Social Entrepreneurship has supported the world’s leading social innovators in their efforts to create a more just, equitable, and sustainable world. The Schwab Foundation provides unparalleled platforms at the regional and global level to highlight and advance leading models of sustainable social innovation.

Learn more at www.schwabfound.org and follow on:
Twitter: https://twitter.com/schwabfound
Facebook: https://www.facebook.com/schwabfound/
LinkedIn: https://www.linkedin.com/company/schwab-foundation-for-social-entrepreneurship

Jubilant Bhartia Foundation (JBF), established in 2007, is the not-for-profit organisation of the Jubilant Bhartia Group. It focuses on conceptualising and implementing the Corporate Social Responsibility initiatives (CSR) for the Group. The Jubilant Bhartia Foundation’s activities include various community development work, healthcare programs, cultural and sports events, environmental preservation initiatives, vocational training, women empowerment, educational activities and promotion of Social Entrepreneurship.

www.jubilantbhartiafoundation.com
Learn more at www.jubilantbhartiafoundation.com and follow on:
Twitter: https://twitter.com/indiaseoy ;
Facebook: https://www.facebook.com/IndiaSEOY
LinkedIn: https://in.linkedin.com/company/jubilantbhartiafoundation

For media queries, please contact:
Vivek Prakash
Jubilant Bhartia Foundation;
Ph: +91 120 436 1804/ 1811;
E-mail: vivek.prakash@jubl.com

Mr. Perfetti has more than 20 years of experience across diverse businesses and global markets with expertise in Strategy, Sales, Marketing and Business Development. He has led business transformation and expansion programs working in reputed names including Accenture and Astrazeneca among others. Prior to joining Jubilant Biosys, Mr. Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer and was responsible for strategizing and executing the company’s growth plan and ramping up the global scale-up and commercial service business.

Commenting on his joining, Mr. Shyam S Bhartia, Chairman and Mr Hari S Bhartia Co-Chairman and Managing Director, Jubilant Pharmova said “Jubilant Biosys is delighted to have Giuliano come on board as we make rapid progress in expanding our drug discovery services and CDMO business through investments in infrastructure and new capacity.”

“I am thrilled to be joining the Jubilant Bhartia Group at such a pivotal time of growth and investment bringing a fully integrated offering from Drug Discovery to Development and Commercial Production.” said Mr. Giuliano Perfetti on his appointment.

About Jubilant Biosys Limited

Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development services for global pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in functional services in chemistry including- computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery expertise with a track record of working on over 80 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.

For more info: www.jubilantbiosys.com

for Business Development Contact:
Ravichandran S
bd@jubilantbiosys.com

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles and Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. Jubilant Biosys Limited provides Contract Research and Development Services through three world class research centres in Bangalore, Noida and Greater Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of around 5,800 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com.